Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.51
-0.35 (-2.21%)
At close: May 18, 2026, 4:00 PM EDT
15.50
-0.01 (-0.06%)
Pre-market: May 19, 2026, 6:26 AM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $30.18. The average 1-year stock price forecast is 94.58% higher than the current stock price, while the lowest is $23 (+48.29%) and the highest is $41 (+164.35%).
Price Target: $30.18 (+94.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 5 | 7 | 7 | 6 | 6 | 6 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +93.42% | May 18, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +106.32% | Apr 27, 2026 |
| Needham | Needham | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +67.63% | Apr 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +106.32% | Apr 10, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +80.53% | Apr 9, 2026 |
Financial Forecast
Revenue This Year
53.36M
from 83.98M
Decreased by -36.46%
Revenue Next Year
82.79M
from 53.36M
Increased by 55.15%
EPS This Year
-3.01
from -3.05
EPS Next Year
-2.86
from -3.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 85.3M | 228.1M | ||||||
| Avg | 53.4M | 82.8M | ||||||
| Low | 39.5M | 41.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6% | 327.4% | ||||||
| Avg | -36.5% | 55.1% | ||||||
| Low | -52.9% | -22.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.46 | -2.10 | ||||||
| Avg | -3.01 | -2.86 | ||||||
| Low | -3.21 | -3.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.